Suppliers and packagers for LUNESTA

Lunesta (eszopiclone) is supplied in the U.S. by a limited set of branded manufacturing and distribution channels, with the active pharmaceutical ingredient (API) sourced from a broader global contractor network. The practical supplier universe depends on product market (U.S. commercial vs. hospital), dosage strength (1 mg, 2 mg, 3 mg), and whether the supply chain is branded (under current FDA labeling) or contract manufacturing for authorized distributors.

Who supplies Lunesta in the U.S. and what companies are on the label?

Short answer: Lunesta is branded and marketed in the U.S. by its NDA holder/brand owner, with manufacturing performed by contract manufacturing organizations (CMOs) and the product distributed through authorized wholesale channels. The specific “supplier” entities that matter for operations are the drug-product manufacturer(s) listed on FDA labeling/packaging and the API suppliers behind the scenes. Publicly accessible identification of the underlying API suppliers is incomplete, but the drug-product manufacturers and distribution channel are traceable.

What’s the branded company behind Lunesta?

Short answer: Lunesta is marketed under the trademark name “Lunesta,” with the NDA/labeling information tied to the brand’s marketing authorization in the U.S.

Which manufacturer(s build Lunesta tablets?

Short answer: Lunesta tablet manufacturing is performed by one or more drug-product manufacturers listed in U.S. labeling (and/or in FDA submissions reflected in label trade dress). Identifying the exact manufacturer per strength requires label-specific verification.

How do wholesale “suppliers” differ from manufacturers?

Wholesale supply for Lunesta typically runs through:

• Authorized distributors and wholesalers that handle branded medicines at scale
• Pharmacy benefit and group purchasing channel intermediaries
• Contract distribution arrangements supporting long-term supply

These entities are operationally relevant for procurement, but they do not replace the underlying manufacturing bottleneck risk.

What companies produce eszopiclone API for Lunesta?

Short answer: The API production base for eszopiclone is global and contractor-heavy, with API sourced from specialized chemical manufacturing facilities in multiple jurisdictions. Public sources rarely provide a clean one-to-one mapping from API suppliers to the final marketed product.

What typically determines which API supplier wins?

Key operational selection drivers:

• Ability to meet cGMP and DMF/CEP requirements under the brand’s submission
• Consistent impurity profile and polymorph control
• Supply continuity and lead time under controlled-substance licensing constraints
• Capacity for commercial volumes across strength-specific batches

How does controlled-substance status affect sourcing?

Lunesta (eszopiclone) is a Schedule IV controlled substance. That changes:

• Distribution compliance requirements
• Secure logistics and inventory handling
• Reporting, audit trail, and diversion-control obligations

These constraints narrow the set of distributors who can run the product through certain channels, even when manufacturing capacity exists.

What contract manufacturers make Lunesta tablets?

Short answer: Contract manufacturers (CMOs) produce Lunesta tablets under the brand holder’s quality system and submission requirements. The manufacturing site(s) are the most actionable “suppliers” for technical transfer and supply continuity analysis.

What should procurement teams check in supplier qualification?

For each potential tablet manufacturer or API-to-finish pathway, the supplier qualification review should confirm:

• cGMP compliance and inspection history at the drug-product site
• Batch traceability and stability program alignment with the approved shelf-life
• Controlled substance handling approvals and secure warehousing capability
• Ability to support strength-level supply (1 mg, 2 mg, 3 mg)
• Packaging configuration compatibility with U.S. distribution (NDC-level)

How does the tablet strength change the supplier footprint?

Short answer: Each strength can run on separate campaigns and lines, which means supply constraints can be strength-specific even when the “same” manufacturer is involved.

Why 1 mg, 2 mg, and 3 mg may have different batch schedules

Strength-level manufacturing differences can reflect:

• Separate compression and coating runs
• Distinct blister or bottle packaging SKUs
• Demand-driven production scheduling
• Different batch size planning and raw material availability

For buyers, that means supply interruptions can hit one strength first.

What are the key supply-chain risks for Lunesta (eszopiclone)?

Short answer: The biggest operational risks are capacity concentration, controlled-substance logistics, and impurity/specification excursions tied to API sourcing and tablet processing.

Where do delays typically originate?

Common failure points:

• API lead times and retesting cycles if impurity bands drift
• Tablet manufacturing capacity constraints (compression, coating, packaging)
• Blister/bottle packaging shortages
• Distribution compliance delays tied to controlled-substance audits
• QC release backlog during peak production periods

How to benchmark supplier robustness

Procurement and business teams typically benchmark:

• Annual production capacity and utilization rate
• Batch disposition lead time (QC release)
• Redundancy for packaging formats
• History of FDA compliance actions at the drug-product site

What “authorized distributors” supply Lunesta to hospitals and pharmacies?

Short answer: Lunesta is distributed through the U.S. wholesale drug distribution network, typically via licensed wholesalers and group purchasing organizations (GPOs). These distributors are the practical purchasing suppliers for clinics, IDNs, and retail pharmacies.

How distributors affect availability during constrained supply

When supply tightens, distributors:

• Allocate inventory by account
• Enforce ordering limits
• Prioritize contracted accounts (GPO terms)
• Manage substitutions only if authorized by product and labeling rules

How do generic entrants change supplier dynamics for Lunesta?

Short answer: Generic market entries expand the number of drug-product manufacturers and API-to-finish routes, which can increase supply resilience. They also change price distribution and procurement negotiation leverage.

What happens when generics launch

Once generics are on the market, the supply landscape changes in three ways:

• More DMF-linked API routes for eszopiclone
• More tablet manufacturing sites competing for contracts
• Lower average price and more stable lead times for purchasers

What to watch commercially

• Which manufacturers are active at the NDC level
• Whether shortages are brand-only or extend across generics
• Allocation patterns during shortages and whether they correlate with specific manufacturing sites

Key Takeaways

• “Suppliers” for Lunesta split into two layers: drug-product manufacturers (tablet/packaging) and downstream authorized wholesalers that fulfill orders to pharmacies and providers.
• The API supply base for eszopiclone is global and not cleanly exposed through public documentation, while drug-product manufacturer(s) are identifiable through U.S. labeling and regulatory filings.
• Lunesta’s controlled-substance status tightens logistics and narrows the operationally eligible distribution and secure-handling chain.
• Strength-level manufacturing campaigns (1 mg, 2 mg, 3 mg) can create strength-specific shortages even when the same manufacturer is involved.
• Generic competition typically broadens the supplier base and reduces procurement risk, changing allocation dynamics during constrained supply periods.

FAQs

1. Which companies are listed as the manufacturer for Lunesta tablets on U.S. packaging/labeling?
2. Does Lunesta’s Schedule IV status limit which distributors can supply hospitals and pharmacies?
3. Are the API suppliers for eszopiclone publicly disclosed through FDA records or DMFs?
4. How can procurement teams identify strength-specific manufacturing capacity constraints for Lunesta?
5. When generic eszopiclone tablets launch, does supply risk shift from the branded manufacturer to multiple CMO sites?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/